AYTU BIOPHARMA, INC: net property, plant and equipment
Net property, plant and equipment for AYTU BIOPHARMA, INC. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All AYTU BIOPHARMA, INC financial histories
What this measure means
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
Exact concept: us-gaap:PropertyPlantAndEquipmentNet. Each value is a balance at the reporting date, not a flow earned over a year. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2011-08-31 to 2025-06-30. The SEC response was captured on 2026-09-20.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| At date | 2025-06-30 | 532,000 | USD | 2025-09-23 | 10-K · 0001437749-25-029723 |
| At date | 2024-06-30 | 693,000 | USD | 2025-09-23 | 10-K · 0001437749-25-029723 |
| At date | 2023-06-30 | 1,815,000 | USD | 2024-09-26 | 10-K · 0001437749-24-030062 |
| At date | 2020-06-30 | 258,516 | USD | 2020-10-06 | 10-K · 0001654954-20-010891 |
| At date | 2019-06-30 | 203,733 | USD | 2020-10-06 | 10-K · 0001654954-20-010891 |
| At date | 2018-06-30 | 218,684 | USD | 2019-09-26 | 10-K · 0001654954-19-011147 |
| At date | 2017-06-30 | 647,254 | USD | 2018-09-06 | 10-K · 0001213900-18-012209 |
| At date | 2016-06-30 | 231,430 | USD | 2017-08-31 | 10-K · 0001144204-17-046061 |
| At date | 2015-06-30 | 29,706 | USD | 2016-09-01 | 10-K · 0001144204-16-122393 |
| At date | 2014-06-30 | 57,246 | USD | 2015-09-28 | 10-K · 0001193125-15-333046 |
| At date | 2013-08-31 | 7,519 | USD | 2014-11-26 | 10-K · 0001079974-14-000837 |
| At date | 2012-08-31 | 12,461 | USD | 2014-11-26 | 10-K · 0001079974-14-000837 |
| At date | 2011-08-31 | 18,611 | USD | 2012-11-29 | 10-K · 0001079974-12-000632 |
Related financial histories
- AYTU BIOPHARMA, INC: total assets
- AYTU BIOPHARMA, INC: total liabilities
- AYTU BIOPHARMA, INC: stockholders equity
- AYTU BIOPHARMA, INC: cash and cash equivalents
- AYTU BIOPHARMA, INC: net income or loss
- AYTU BIOPHARMA, INC: operating cash flow
- AYTU BIOPHARMA, INC: capital expenditure payments
- AYTU BIOPHARMA, INC: revenue
- AYTU BIOPHARMA, INC: contract revenue excluding tax
- AYTU BIOPHARMA, INC: financing cash flow
- AYTU BIOPHARMA, INC: investing cash flow
- AYTU BIOPHARMA, INC: retained earnings or deficit
- AYTU BIOPHARMA, INC: basic weighted-average shares
- AYTU BIOPHARMA, INC: diluted weighted-average shares
- AYTU BIOPHARMA, INC: basic earnings per share
- AYTU BIOPHARMA, INC: diluted earnings per share
- AYTU BIOPHARMA, INC: income tax expense or benefit
- AYTU BIOPHARMA, INC: share-based compensation expense
- AYTU BIOPHARMA, INC: operating income or loss
- AYTU BIOPHARMA, INC: current assets
- AYTU BIOPHARMA, INC: interest expense
- AYTU BIOPHARMA, INC: current liabilities
- AYTU BIOPHARMA, INC: current accounts payable
- AYTU BIOPHARMA, INC: goodwill carrying amount
- AYTU BIOPHARMA, INC: net finite-lived intangible assets
- AYTU BIOPHARMA, INC: net current accounts receivable
- AYTU BIOPHARMA, INC: operating expenses
- AYTU BIOPHARMA, INC: net inventory
- AYTU BIOPHARMA, INC: gross profit
- AYTU BIOPHARMA, INC: cost of revenue
- AYTU BIOPHARMA, INC: selling, general and administrative expense
- AYTU BIOPHARMA, INC: research and development expense
Inspect the source
- Entity
- AYTU BIOPHARMA, INC / CIK 0001385818
- Captured
- 2026-09-20T07:58:53.461Z
- SEC response SHA-256
3b664ab8156647d48cbdda6c8eb0b5f1ac4147c50f45c9bb53fa74b58565a69b
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001385818.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))